ArticleVirus research2026
HMPV-TherResDB: Comprehensive human metapneumovirus (HMPV) database for sequence-structure annotations, vaccine resources, and therapeutics research.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (HMPV), a current escalating health issue, causes respiratory complications in young children, the elderly, and immunocompromised individuals. To date, no specific treatment is available; thus, to support vaccine and therapeutic development, we present HMPV-TherRes: a specialized database for HMPV research. This platform integrates a wealth of genomic, proteomic, structural, and immunological data, as well as target-specific drugs, RNA-based therapeutics, and CRISPR-based designs, offering an invaluable resource for advancing both basic and clinical research. The database integrates data generated through state-of-the-art and AI-powered algorithms. The database hosts 618 annotated genomes from various parts of the world, along with protein information, including their physicochemical properties, and experimentally derived or AlphaFold-predicted 3D structures. Moreover, immune resources are a central feature, encompassing detailed information on the predicted and experimentally reported cytotoxic T lymphocyte (CTL) epitopes, helper T lymphocyte (HTL) epitopes (IFN ±), and B-cell epitopes. Additionally, it includes curated datasets, multi-epitope vaccines, and mRNA-based vaccine candidates, underscoring its utility in vaccine design and development. The database also provides data on different drugs targeting hMPV, along with extensive RNA-therapeutic resources, such as siRNAs and miRNAs, which are instrumental in gene-silencing applications. Further expanding its scope, HMPV-TherRes includes CRISPR-based sgRNA designs for both Cas9 and Cas13, enabling targeted genome editing and regulation of the transcriptome. HMPV-TherRes is a versatile repository bridging experimental and computational studies, consolidating diverse resources to support vaccine design, RNA therapeutics, and drug development. It advances understanding of hMPV biology, accelerating efforts to combat the pathogen. This centralized, user-friendly platform represents a significant advancement in virology, enabling researchers to develop novel interventions against HMPV. The database can be accessed through: https://ddd.agounikhanlabs.com/hmpvetherpresdb/index.php.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.